Search

Your search keyword '"Robinson, Bruce"' showing total 3,994 results
Start Over Author "Robinson, Bruce"
3,994 results on '"Robinson, Bruce"'

204. Cabozantinib for previously treated radioiodine‐refractory differentiated thyroid cancer: Updated results from the phase 3 COSMIC‐311 trial

Author

Brose, Marcia S., primary, Robinson, Bruce G., additional, Sherman, Steven I., additional, Jarzab, Barbara, additional, Lin, Chia‐Chi, additional, Vaisman, Fernanda, additional, Hoff, Ana O., additional, Hitre, Erika, additional, Bowles, Daniel W., additional, Sen, Suvajit, additional, Oliver, Jennifer W., additional, Banerjee, Kamalika, additional, Keam, Bhumsuk, additional, and Capdevila, Jaume, additional

Published
2022
Full Text
View/download PDF

206. Oral Health-Related Quality of Life, A Proxy of Poor Outcomes in Patients on Peritoneal Dialysis

Author

Purisinsith, Sirirat, primary, Kanjanabuch, Patnarin, additional, Phannajit, Jeerath, additional, Kanjanabuch, Talerngsak, additional, Puapatanakul, Pongpratch, additional, Johnson, David W., additional, Pongpirul, Krit, additional, Perl, Jeffrey, additional, Robinson, Bruce, additional, Tungsanga, Kriang, additional, Praditpornsilpa, Kearkiat, additional, Chutsawan, Tanittha, additional, Triamamornwooth, Kanittha, additional, Towannang, Piyaporn, additional, Lorvinitnun, Pichet, additional, Sritippayawan, Suchai, additional, Halue, Guttiga, additional, Tangjittrong, Kittisak, additional, Poonvivatchaikarn, Ussanee, additional, Buranaosot, Somphon, additional, Nilvarangkul, Sukit, additional, Somboonsilp, Wanida, additional, Wongtrakul, Pimpong, additional, Boonyakrai, Chanchana, additional, Narenpitak, Surapong, additional, Tatiyanupanwong, Sajja, additional, Saikong, Wadsamon, additional, Uppamai, Sriphrae, additional, Phisutrattanaporn, Jarubut, additional, Panyatong, Setthapon, additional, Taruangsri, Puntapong, additional, Chieochanthanakij, Rutchanee, additional, Lounseng, Niwat, additional, Wongpiang, Angsuwarin, additional, Treamtrakanpon, Worapot, additional, Rattanasoonton, Peerapach, additional, Lukrat, Narumon, additional, Songviriyavithaya, Phichit, additional, Parinyasiri, Uraiwan, additional, and Cheawchanwattana, Areewan, additional

Published
2022
Full Text
View/download PDF

220. Cure Glomerulonephropathy Pathology Classification and Core Scoring Criteria, Reproducibility, and Clinicopathologic Correlations

Author

Palmer, Matthew B, Royal, Virginie, Jennette, J. Charles, Smith, Abigail R., Liu, Qian, Ambruzs, Josephine M., Andeen, Nicole K., D’Agati, Vivette D., Fogo, Agnes B., Gaut, Joseph, Gbadegesin, Rasheed A., Greenbaum, Larry A., Hou, Jean, Helmuth, Margaret E, Lafayette, Richard A., Liapis, Helen, Robinson, Bruce, Stokes, Michael B., Twombley, Katherine, Yin, Hong, and Nast, Cynthia C.

Abstract

Introduction:Cure Glomerulonephropathy (CureGN) is an observational cohort study of patients with minimal change disease (MCD), focal segmental glomerulosclerosis (FSGS), membranous nephropathy (MN), or IgA nephropathy. We developed a conventional, consensus-based scoring system to document pathologic features for application across multiple pathologists and herein describe the protocol, reproducibility, and correlation with clinical parameters at biopsy. Methods:Definitions were established for glomerular, tubular, interstitial, and vascular lesions evaluated semiquantitatively using digitized light microscopy slides and electron micrographs, and reported immunofluorescence. Cases with curated pathology materials as of April 2019 were scored by a randomly assigned pathologist, with at least 10% of cases scored by a second pathologist. Scoring reproducibility was assessed using Gwet’s agreement coefficient (AC)1 statistic and correlations with clinical variables were performed. Results:Of 800 scored biopsies (134 MCD, 194 FSGS, 206 MN, 266 IgA), 94 were scored twice (11.8%). Of 60 pathology features, 46 (76.7%) demonstrated excellent (AC1>0.8), and 12 (20.0%) had good (AC1 0.6–0.8) reproducibility. Mesangial hypercellularity scored as absent, focal, or diffuse had moderate reproducibility (AC1 = 0.58), but good reproducibility (AC1 = 0.71) when scored as absent or focal versus diffuse. The percent glomeruli scored as no lesions had fair reproducibility (AC1 = 0.34). Strongest correlations between pathologic features and clinical characteristics at biopsy included interstitial inflammation, interstitial fibrosis, and tubular atrophy with estimated glomerular filtration rate, foot process effacement with urine protein/creatinine ratio, and active crescents with hematuria. Conclusions:Most scored pathology features showed excellent reproducibility, demonstrating consistency for these features across multiple pathologists. Correlations between certain pathologic features and expected clinical characteristics show the value of this approach for future studies on clinicopathologic correlations and biomarker discovery.

Published
2023
Full Text
View/download PDF

222. Medical and Surgical Care of Patients With Mesothelioma and Their Relatives Carrying Germline BAP1 Mutations

Author

Carbone, Michele, primary, Pass, Harvey I., additional, Ak, Guntulu, additional, Alexander, H. Richard, additional, Baas, Paul, additional, Baumann, Francine, additional, Blakely, Andrew M., additional, Bueno, Raphael, additional, Bzura, Aleksandra, additional, Cardillo, Giuseppe, additional, Churpek, Jane E., additional, Dianzani, Irma, additional, De Rienzo, Assunta, additional, Emi, Mitsuru, additional, Emri, Salih, additional, Felley-Bosco, Emanuela, additional, Fennell, Dean A., additional, Flores, Raja M., additional, Grosso, Federica, additional, Hayward, Nicholas K., additional, Hesdorffer, Mary, additional, Hoang, Chuong D., additional, Johansson, Peter A., additional, Kindler, Hedy L., additional, Kittaneh, Muaiad, additional, Krausz, Thomas, additional, Mansfield, Aaron, additional, Metintas, Muzaffer, additional, Minaai, Michael, additional, Mutti, Luciano, additional, Nielsen, Maartje, additional, O’Byrne, Kenneth, additional, Opitz, Isabelle, additional, Pastorino, Sandra, additional, Pentimalli, Francesca, additional, de Perrot, Marc, additional, Pritchard, Antonia, additional, Ripley, Robert Taylor, additional, Robinson, Bruce, additional, Rusch, Valerie, additional, Taioli, Emanuela, additional, Takinishi, Yasutaka, additional, Tanji, Mika, additional, Tsao, Anne S., additional, Tuncer, A. Murat, additional, Walpole, Sebastian, additional, Wolf, Andrea, additional, Yang, Haining, additional, Yoshikawa, Yoshie, additional, Zolondick, Alicia, additional, Schrump, David S., additional, and Hassan, Raffit, additional

Published
2022
Full Text
View/download PDF

223. A Retrospective Cohort Study with Validation of Predictors of Differentiated Thyroid Cancer Outcomes

Author

Wijewardene, Ayanthi, primary, Gill, Anthony J., additional, Gild, Matti, additional, Learoyd, Diana L., additional, Glover, Anthony Robert, additional, Sywak, Mark, additional, Sidhu, Stan, additional, Roach, Paul, additional, Schembri, Geoffrey, additional, Hoang, Jeremy, additional, Robinson, Bruce, additional, Tacon, Lyndal, additional, and Clifton-Bligh, Roderick, additional

Published
2022
Full Text
View/download PDF

226. Effectiveness and Tolerance of Renin-Angiotensin System Inhibitors With Aging in Chronic Kidney Disease

Author

Villain, Cédric, primary, Metzger, Marie, additional, Liabeuf, Sophie, additional, Hamroun, Aghilès, additional, Laville, Solene, additional, Mansencal, Nicolas, additional, Combe, Christian, additional, Fouque, Denis, additional, Frimat, Luc, additional, Jacquelinet, Christian, additional, Laville, Maurice, additional, Ayav, Carole, additional, Briançon, Serge, additional, Pecoits-Filho, Roberto, additional, Hannedouche, Thierry, additional, Stengel, Bénédicte, additional, Massy, Ziad A., additional, Cannet, Dorothée, additional, Herpe, Yves-Edouard, additional, Pascal, Christophe, additional, Robinson, Bruce M., additional, Lange, Céline, additional, Legrand, Karine, additional, Speyer, Elodie, additional, Moulin, Bruno, additional, Mailliez, Sébastien, additional, Lebrun, Gaétan, additional, Magnant, Eric, additional, Choukroun, Gabriel, additional, Deroure, Benjamin, additional, Lacraz, Adeline, additional, Lambrey, Guy, additional, Bourdenx, Jean Philippe, additional, Essig, Marie, additional, Lobbedez, Thierry, additional, Azar, Raymond, additional, Sekhri, Hacène, additional, Smati, Mustafa, additional, Jamali, Mohamed, additional, Klein, Alexandre, additional, Delahousse, Michel, additional, Martin, Séverine, additional, Landru, Isabelle, additional, Thervet, Eric, additional, Lang, Philippe, additional, Belenfant, Xavier, additional, Urena, Pablo, additional, Vela, Carlos, additional, Chauveau, Dominique, additional, Panescu, Viktor, additional, Noel, Christian, additional, Glowacki, François, additional, Hoffmann, Maxime, additional, Hourmant, Maryvonne, additional, Besnier, Dominique, additional, Testa, Angelo, additional, Kuentz, François, additional, Zaoui, Philippe, additional, Chazot, Charles, additional, Juillard, Laurent, additional, Burtey, Stéphane, additional, Keller, Adrien, additional, and Kamar, Nassim, additional

Published
2022
Full Text
View/download PDF

231. Medical and Surgical Care of Patients With Mesothelioma and Their Relatives Carrying Germline BAP1 Mutations

Author

Carbone, Michele, Pass, Harvey I., Ak, Guntulu, Alexander, H. Richard, Baas, Paul, Baumann, Francine, Blakely, Andrew M., Bueno, Raphael, Bzura, Aleksandra, Cardillo, Giuseppe, Churpek, Jane E., Dianzani, Irma, De Rienzo, Assunta, Emi, Mitsuru, Emri, Salih, Felley-Bosco, Emanuela, Fennell, Dean A., Flores, Raja M., Grosso, Federica, Hayward, Nicholas K., Hesdorffer, Mary, Hoang, Chuong D., Johansson, Peter A., Kindler, Hedy L., Kittaneh, Muaiad, Krausz, Thomas, Mansfield, Aaron, Metintas, Muzaffer, Minaai, Michael, Mutti, Luciano, Nielsen, Maartje, O'Byrne, Kenneth, Opitz, Isabelle, Pastorino, Sandra, Pentimalli, Francesca, de Perrot, Marc, Pritchard, Antonia, Ripley, Robert Taylor, Robinson, Bruce, Rusch, Valerie, Taioli, Emanuela, Takinishi, Yasutaka, Tanji, Mika, Tsao, Anne S., Tuncer, A. Murat, Walpole, Sebastian, Wolf, Andrea, Yang, Haining, Yoshikawa, Yoshie, Zolondick, Alicia, Schrump, David S., Hassan, Raffit, Carbone, Michele, Pass, Harvey I., Ak, Guntulu, Alexander, H. Richard, Baas, Paul, Baumann, Francine, Blakely, Andrew M., Bueno, Raphael, Bzura, Aleksandra, Cardillo, Giuseppe, Churpek, Jane E., Dianzani, Irma, De Rienzo, Assunta, Emi, Mitsuru, Emri, Salih, Felley-Bosco, Emanuela, Fennell, Dean A., Flores, Raja M., Grosso, Federica, Hayward, Nicholas K., Hesdorffer, Mary, Hoang, Chuong D., Johansson, Peter A., Kindler, Hedy L., Kittaneh, Muaiad, Krausz, Thomas, Mansfield, Aaron, Metintas, Muzaffer, Minaai, Michael, Mutti, Luciano, Nielsen, Maartje, O'Byrne, Kenneth, Opitz, Isabelle, Pastorino, Sandra, Pentimalli, Francesca, de Perrot, Marc, Pritchard, Antonia, Ripley, Robert Taylor, Robinson, Bruce, Rusch, Valerie, Taioli, Emanuela, Takinishi, Yasutaka, Tanji, Mika, Tsao, Anne S., Tuncer, A. Murat, Walpole, Sebastian, Wolf, Andrea, Yang, Haining, Yoshikawa, Yoshie, Zolondick, Alicia, Schrump, David S., and Hassan, Raffit

Abstract

The most common malignancies that develop in carriers of BAP1 germline mutations include diffuse malignant mesothelioma, uveal and cutaneous melanoma, renal cell carcinoma, and less frequently, breast cancer, several types of skin carcinomas, and other tumor types. Mesotheliomas in these patients are significantly less aggressive, and patients require a multidisciplinary approach that involves genetic counseling, medical genetics, pathology, surgical, medical, and radiation oncology expertise. Some BAP1 carriers have asymptomatic mesothelioma that can be followed by close clinical observation without apparent adverse outcomes: they may survive many years without therapy. Others may grow aggressively but very often respond to therapy. Detecting BAP1 germline mutations has, therefore, substantial medical, social, and economic impact. Close monitoring of these patients and their relatives is expected to result in prolonged life expectancy, improved quality of life, and being cost-effective. The co-authors of this paper are those who have published the vast majority of cases of mesothelioma occurring in patients carrying inactivating germline BAP1 mutations and who have studied the families affected by the BAP1 cancer syndrome for many years. This paper reports our experience. It is intended to be a source of information for all physicians who care for patients carrying germline BAP1 mutations. We discuss the clinical presentation, diagnostic and treatment challenges, and our recommendations of how to best care for these patients and their family members, including the potential economic and psychosocial impact.

Published
2022

232. LIBRETTO-531: A Phase III Study of Selpercatinib in Multikinase Inhibitor-Naïve

Author

Wirth, Lori J, Brose, Marcia S, Elisei, Rossella, Capdevila, Jaume, Hoff, Ana O, Hu, Mimi I, Tahara, Makoto, Robinson, Bruce, Gao, Ming, Xia, Meng, Maeda, Patricia, Sherman, Eric, Wirth, Lori J, Brose, Marcia S, Elisei, Rossella, Capdevila, Jaume, Hoff, Ana O, Hu, Mimi I, Tahara, Makoto, Robinson, Bruce, Gao, Ming, Xia, Meng, Maeda, Patricia, and Sherman, Eric

Abstract

Selpercatinib is a first-in-class, highly selective and potent, central nervous system-active RET kinase inhibitor. In the phase I/II trial, selpercatinib demonstrated clinically meaningful antitumor activity with manageable toxicity in heavily pre-treated and treatment-naive patients with RET-mutant medullary thyroid cancer (MTC). LIBRETTO-531 (NCT04211337) is a multicenter, open-label, randomized, controlled, phase III trial comparing selpercatinib to cabozantinib or vandetanib in patients with advanced/metastatic RET-mutant MTC. The primary objective is to compare progression-free survival (per RECIST 1.1) by blinded independent central review of patients with progressive, advanced, multikinase inhibitor-naive, RET-mutant MTC treated with selpercatinib versus cabozantinib or vandetanib. Key secondary objectives are to compare other efficacy outcomes (per RECIST 1.1) and tolerability of selpercatinib versus cabozantinib or vandetanib.

Published
2022

233. Availability and prioritisation of COVID-19 vaccines among patients with advanced chronic kidney disease and kidney failure during the height of the pandemic: a global survey by the International Society of Nephrology

Author

Wijewickrama, Eranga S, Abdul Hafidz, Muhammad Iqbal, Robinson, Bruce M, Johnson, David W, Liew, Adrian, Dreyer, Gavin, Caskey, Fergus J, Bello, Aminu K, Zaidi, Deenaz, Damster, Sandrine, Salaro, Silvia, Luyckx, Valerie Ann; https://orcid.org/0000-0001-7066-8135, Bajpai, Divya; https://orcid.org/0000-0003-2294-0506, Wijewickrama, Eranga S, Abdul Hafidz, Muhammad Iqbal, Robinson, Bruce M, Johnson, David W, Liew, Adrian, Dreyer, Gavin, Caskey, Fergus J, Bello, Aminu K, Zaidi, Deenaz, Damster, Sandrine, Salaro, Silvia, Luyckx, Valerie Ann; https://orcid.org/0000-0001-7066-8135, and Bajpai, Divya; https://orcid.org/0000-0003-2294-0506

Abstract

OBJECTIVE Patients with advanced chronic kidney disease (CKD) or kidney failure receiving replacement therapy (KFRT) are highly vulnerable to COVID-19 infection, morbidity and mortality. Vaccination is effective, but access differs around the world. We aimed to ascertain the availability, readiness and prioritisation of COVID-19 vaccines for this group of patients globally. SETTING AND PARTICIPANTS Collaborators from the International Society of Nephrology (ISN), Dialysis Outcomes and Practice Patterns Study and ISN-Global Kidney Health Atlas developed an online survey that was administered electronically to key nephrology leaders in 174 countries between 2 July and 4 August 2021. RESULTS Survey responses were received from 99 of 174 countries from all 10 ISN regions, among which 88/174 (50%) were complete. At least one vaccine was available in 96/99 (97%) countries. In 71% of the countries surveyed, patients on dialysis were prioritised for vaccination, followed by patients living with a kidney transplant (KT) (62%) and stage 4/5 CKD (51%). Healthcare workers were the most common high priority group for vaccination. At least 50% of patients receiving in-centre haemodialysis, peritoneal dialysis or KT were estimated to have completed vaccination at the time of the survey in 55%, 64% and 51% of countries, respectively. At least 50% of patients in all three patient groups had been vaccinated in >70% of high-income countries and in 100% of respondent countries in Western Europe.The most common barriers to vaccination of patients were vaccine hesitancy (74%), vaccine shortages (61%) and mass vaccine distribution challenges (48%). These were reported more in low-income and lower middle-income countries compared with high-income countries. CONCLUSION Patients with advanced CKD or KFRT were prioritised in COVID-19 vaccination in most countries. Multiple barriers led to substantial variability in the successful achievement of COVID-19 vaccination across the world, with high

Published
2022

235. NRASQ61R Mutation-specific Immunohistochemistry Also Identifies the HRASQ61R Mutation in Medullary Thyroid Cancer and May Have a Role in Triaging Genetic Testing for MEN2

Author

Reagh, Jessica, Bullock, Martyn, Andrici, Juliana, Turchini, John, Sioson, Loretta, Clarkson, Adele, Watson, Nicole, Sheen, Amy, Lim, Grace, Delbridge, Leigh, Sidhu, Stan, Sywak, Mark, Aniss, Ahmad, Shepherd, Phillip, Ng, Daniel, Oei, Paul, Field, Michael, Learoyd, Diana, Robinson, Bruce G., Clifton-Bligh, Roderick J., and Gill, Anthony J.

Published
2017
Full Text
View/download PDF

240. Cabozantinib versus placebo in patients with radioiodine-refractory differentiated thyroid cancer (DTC) who have progressed after prior VEGFR-Targeted yherapy: updated results from the phase 3 COSMIC-311 trial and prespecified subgroup analyses based on prior therapy

Author

Durante, Cosimo, primary, Brose, Marcia, additional, Robinson, Bruce, additional, Sherman, Steven I, additional, Jarzab, Barbara, additional, Lin, Chia-Chi, additional, Vaisman, Fernanda, additional, Hoff, Ana O, additional, Hitre, Erika, additional, Bowles, Daniel W, additional, Sen, Suvajit, additional, Patel, Purvi, additional, Keam, Bhumsuk, additional, and Capdevila, Jaume, additional

Published
2022
Full Text
View/download PDF

241. Effect of age on efficacy and safety of cabozantinib vs placebo in patients with radioiodine refractory (RAI-R)-differentiated thyroid cancer (DTC) with progression after VEGFR-targeted therapy: subgroup analysis from Phase 3 COSMIC 311 study

Author

Durante, Cosimo, primary, Robinson, Bruce, additional, Sherman, Steven I, additional, Krajewska, Jolanta, additional, Lin, Chia-Chi, additional, Vaisman, Fernanda, additional, Hoff, Ana O, additional, Hitre, Erika, additional, Bowles, Daniel W, additional, Hernando, Jorge, additional, Banerjee, Kamalika, additional, Levytskyy, Roman M, additional, Oliver, Jennifer W, additional, Keam, Bhumsuk, additional, Capdevila, Jaume, additional, and Brose, Marcia, additional

Published
2022
Full Text
View/download PDF

243. MO496: Serum Urea Levels and Cardiovascular Disease in Patients With Chronic Kidney Disease

Author

Laville, Solene, primary, Couturier, Aymeric, additional, Lambert, Oriane, additional, Metzger, Marie, additional, Nicolas, Mansencal, additional, Jacquelinet, Christian, additional, Laville, Maurice, additional, Frimat, Luc, additional, Fouque, Denis, additional, Combe, Christian, additional, Robinson, Bruce, additional, Stengel, Benedicte, additional, Liabeuf, Sophie, additional, and Massy, Ziad, additional

Published
2022
Full Text
View/download PDF

244. Mortality Trends After Transfer From Peritoneal Dialysis to Hemodialysis

Author

Nadeau-Fredette, Annie-Claire, primary, Sukul, Nidhi, additional, Lambie, Mark, additional, Perl, Jeffrey, additional, Davies, Simon, additional, Johnson, David W., additional, Robinson, Bruce, additional, Van Biesen, Wim, additional, Kramer, Anneke, additional, Jager, Kitty J., additional, Saran, Rajiv, additional, Pisoni, Ronald, additional, Chan, Christopher T., additional, Combes, Gill, additional, Firanek, Catherine, additional, Gomez, Rafael, additional, Jha George, Vivek, additional, Madero, Magdalena, additional, Masakane, Ikuto, additional, Misra, Madhukar, additional, McDonald, Stephen, additional, Mitra, Sandip, additional, Moraes, Thyago, additional, Mukhopadhyay, Puma, additional, Sloand, James, additional, Tong, Allison, additional, and Szeto, Cheuk-Chun, additional

Published
2022
Full Text
View/download PDF

245. A Randomized, Double-Blind Noninferiority Study to Evaluate the Efficacy of the Cabozantinib Tablet at 60 mg Per Day Compared with the Cabozantinib Capsule at 140 mg Per Day in Patients with Progressive, Metastatic Medullary Thyroid Cancer

Author

Capdevila, Jaume, primary, Klochikhin, Arkadiy, additional, Leboulleux, Sophie, additional, Isaev, Pavel, additional, Badiu, Corin, additional, Robinson, Bruce, additional, Hughes, Brett G.M., additional, Keam, Bhumsuk, additional, Parnis, Francis, additional, Elisei, Rossella, additional, Gajate, Pablo, additional, Gan, Hui K., additional, Kapiteijn, Ellen, additional, Locati, Laura, additional, Mangeshkar, Milan, additional, Faoro, Leonardo, additional, Krajewska, Jolanta, additional, and Jarzab, Barbara, additional

Published
2022
Full Text
View/download PDF

246. MO900: Diuretic Prescription Patterns in Haemodialysis Patients: International Variation Reported in the Dopps

Author

Tabibzadeh, Nahid, primary, Wang, Dongyu, additional, Karaboyas, Angelo, additional, Robinson, Bruce, additional, Young, Eric, additional, Schaeffner, Elke, additional, Jacobson, Stefan, additional, Vega, Almudena, additional, Al Rukhaimi, Mona, additional, Nitta, Kosaku, additional, Bieber, Brian, additional, Port, Friedrich, additional, and Antonio Urena Torres, Pablo, additional

Published
2022
Full Text
View/download PDF

247. MO863: Electronic Patient Reported Outcome (EPRO) Collection in Dopps: Prospective Study Designed to Understand the Severity and Temporal Changes in Pruritus Symptoms in Hemodialysis Patients

Author

Karaboyas, Angelo, primary, Robinson, Bruce, additional, Albert, Justin, additional, Hogan, Anna, additional, Kane, Lauren, additional, Asgari, Elham, additional, Guebre-Egziabher, Fitsum, additional, Messa, Piergiorgio, additional, Weinreich, Thomas, additional, Walpen, Sebastian, additional, Schaufler, Thilo, additional, and Pisoni, Ronald, additional

Published
2022
Full Text
View/download PDF

248. MO901: Longitudinal Pruritus Assessment in Hemodialysis Patients: 1-Year Course of Symptoms and Associations With Clinical and Patient-Reported Outcomes

Author

Sukul, Nidhi, primary, Zhao, Junhui, additional, Pisoni, Ronald, additional, Walpen, Sebastian, additional, Schaufler, Thilo, additional, Asgari, Elham, additional, Guebre-Egziabher, Fitsum, additional, Abdulrahman Al-Ghonaim, Mohammed, additional, Nitta, Kosaku, additional, Robinson, Bruce, additional, and Karaboyas, Angelo, additional

Published
2022
Full Text
View/download PDF

249. Impact of baseline tumor burden on overall survival in patients with radioiodine‐refractory differentiated thyroid cancer treated with lenvatinib in the SELECT global phase 3 trial

Author

Kiyota, Naomi, primary, Tahara, Makoto, additional, Robinson, Bruce, additional, Schlumberger, Martin, additional, Sherman, Steven I., additional, Leboulleux, Sophie, additional, Lee, Eun Kyung, additional, Suzuki, Takuya, additional, Ren, Min, additional, Fushimi, Kazuma, additional, and Wirth, Lori J., additional

Published
2022
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results